Evaluation of the Therapeutic Potential of Anti-TLR4-Antibody MTS510 in Experimental Stroke and Significance of Different Routes of Application

2016 | journal article. A publication with affiliation to the University of Göttingen.

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Evaluation of the Therapeutic Potential of Anti-TLR4-Antibody MTS510 in Experimental Stroke and Significance of Different Routes of Application​
Andresen, L.; Theodorou, K.; Gruenewald, S.; Czech-Zechmeister, B.; Koennecke, B.; Luehder, F. & Trendelenburg, G.​ (2016) 
PLoS ONE11(2) art. e0148428​.​ DOI: https://doi.org/10.1371/journal.pone.0148428 

Documents & Media

journal.pone.0148428.pdf570.89 kBAdobe PDF

License

Published Version

Attribution 4.0 CC BY 4.0

Details

Authors
Andresen, Lena; Theodorou, Konstantina; Gruenewald, Sarah; Czech-Zechmeister, Bozena; Koennecke, Birte; Luehder, Fred; Trendelenburg, George
Abstract
Toll-like receptors (TLRs) are central sensors for the inflammatory response in ischemia-reperfusion injury. We therefore investigated whether TLR4 inhibition could be used to treat stroke in a standard model of focal cerebral ischemia. Anti-TLR4/MD2-antibody (mAb clone MTS510) blocked TLR4-induced cell activation in vitro, as reported previously. Here, different routes of MTS510 application in vivo were used to study the effects on stroke outcome up to 2d after occlusion of the middle cerebral artery (MCAO) for 45min in adult male C57Bl/6 wild-type mice. Improved neurological performance, reduced infarct volumes, and reduced brain swelling showed that intravascular application of MTS510 had a protective effect in the model of 45min MCAO. Evaluation of potential long-term adverse effects of anti-TLR4-mAb-treament revealed no significant deleterious effect on infarct volumes nor neurological deficit after 14d of reperfusion in a mild model of stroke (15min MCAO). Interestingly, inhibition of TLR4 resulted in an altered adaptive immune response at 48 hours after reperfusion. We conclude that blocking TLR4 by the use of specific mAb is a promising strategy for stroke therapy. However, long-term studies with increased functional sensitivity, larger sampling sizes and use of other species are required before a clinical use could be envisaged.
Issue Date
2016
Status
published
Publisher
Public Library Science
Journal
PLoS ONE 
ISSN
1932-6203
Sponsor
Open-Access-Publikationsfonds 2016

Reference

Citations


Social Media